Paper Details

  1. Home
  2. Paper Details

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.

Author: AuN, ChaiY, ConcinN, CrochiereM, HanS N, HaslundC, JoshiA, KauffmanM, KranichA, LandesmanY, LundB, Mau-SorensenM, MirzaM R, NottrupT, PeenU, RashalT, ShachamS, ShahJ, UmajuridzeZ, UngerT J, Van NieuwenhuysenE, VergoteI B

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2 trial found that selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. The disease control rate was 30% with confirmed partial responses in 8% of ovarian, 9% of endometrial, and 4% of cervical cancer patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent gynecological malignancies. METHODS: In this ph...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ygyno.2019.11.012

データ提供：米国国立医学図書館（NLM）

Selinexor: A New Weapon in the Fight Against Gynecological Cancers

Gynecological cancers, a formidable challenge in the desert of women’s health, often require multiple lines of treatment, sometimes leaving patients with limited options. This research explores the potential of selinexor, an oral inhibitor of Exportin 1 (XPO1), as a new weapon in the fight against recurrent gynecological malignancies. The study investigates the efficacy and safety of selinexor in patients with ovarian, endometrial, and cervical cancers who have undergone multiple prior treatments.

A Potential Oasis in the Desert of Recurrent Cancers

The study found that selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. While the overall response rates were modest, the findings suggest that selinexor may offer a valuable treatment option for patients with limited treatment choices.

Navigating the Desert of Side Effects: Managing Toxicity

As with any new treatment, it’s crucial to understand and manage potential side effects. The study identified several adverse events, including thrombocytopenia, fatigue, anemia, nausea, and hyponatremia. The authors emphasize that these side effects were generally reversible and could be mitigated with supportive care.

Dr. Camel's Conclusion

The quest for effective treatments for gynecological cancers is a journey through a vast and challenging desert. This research offers a potential oasis in the form of selinexor, providing a glimmer of hope for patients with limited options. While the journey continues, this research provides valuable insights into the potential of this drug and its place in the fight against gynecological cancers.

Date :
  1. Date Completed 2020-05-05
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

31822399

DOI: Digital Object Identifier

10.1016/j.ygyno.2019.11.012

Related Literature

Article Analysis
・Side Effects of selinexor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.